Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713048 | 1.00 | IDO1 (0.41) | IDO1EPHX2SCN4AMPLBACE1 | |
| SCHEMBL13548653 | 0.81 | PDE2A (0.42) | IDO1EPHX2SCN4ABACE1PDE2A | |
| Hydrochloric Acid SCHEMBL5703291 | 0.78 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5220846 | 0.78 | CES2 (0.42) | EPHX2SCN4ABACE1PDE2AGRIN2D | |
| SCHEMBL31136730 | 0.77 | PDE2A (0.39) | IDO1BACE1PDE2ACYP1A1CYP1B1 | |
| SCHEMBL17712848 | 0.76 | GRIN2D (0.61) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17712851 | 0.76 | GRIN2D (0.61) | BACE1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28093529 | 0.75 | PDE2A (0.37) | IDO1BACE1PDE2ACYP1A1CYP1B1 | |
| SCHEMBL28093533 | 0.75 | PDE2A (0.37) | IDO1BACE1PDE2ACYP1A1CYP1B1 | |
| SCHEMBL17044413 | 0.75 | LMNA (0.44) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | INDIVIOR UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3212637-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | Indivior UK Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | DRD3, DRD2, DRD4 | IDO1 2625/4885EPHX2 2591/4885SCN4A 1417/4885 |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | IDO1 2572/4885EPHX2 2779/4885SCN4A 1429/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | IDO1 2572/4885EPHX2 2779/4885SCN4A 1429/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | IDO1 2572/4885EPHX2 2779/4885SCN4A 1429/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | IDO1 2572/4885EPHX2 2779/4885SCN4A 1429/4885 |
| US-10239870-B2 | Dopamine D3 receptor antagonists | DRD3, DRD2, DRD4 | IDO1 2625/4885EPHX2 2591/4885SCN4A 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.